Immunovant, Inc. — Director's Dealing 2023

Apr 14, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immunovant, Inc. (IMVT)
CIK: 0001764013
Period of Report: 2023-04-12

Reporting Person: Salzmann Peter (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-04-12	Common Stock	A	243832	—	Acquired	1237764	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-04-12	Stock Option (right to buy)	$14.7	A	316585	Acquired	2033-04-12	Common Stock (316585.0)	Direct

Footnotes

F1: Represents the number of shares underlying restricted stock units awards ("RSUs").

F2: The RSUs vest over four years, with 25% of the RSUs vesting on April 12, 2024 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

F3: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on April 12, 2024 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.